{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T07:11:21Z","timestamp":1768720281171,"version":"3.49.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"28","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1097\/md.0000000000000285","type":"journal-article","created":{"date-parts":[[2015,1,8]],"date-time":"2015-01-08T14:51:29Z","timestamp":1420728689000},"page":"e285","source":"Crossref","is-referenced-by-count":14,"title":["BRAFV600E immunopositive Melanomas Show Low Frequency of Heterogeneity and Association With Epithelioid Tumor Cells"],"prefix":"10.1097","volume":"93","author":[{"given":"Ivana","family":"Verlinden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"van den Hurk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruud","family":"Clarijs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjan P.","family":"Willig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecile M.H.A.","family":"Stallinga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido M.J.M.","family":"Roemen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost J.","family":"van den Oord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"zur Hausen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernst-Jan M.","family":"Speel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique J.L.","family":"Winnepenninckx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-33-20210309","first-page":"89","article-title":"Genetics and epigenetics of cutaneous malignant melanoma: a concert out of tune.","volume":"1826","author":"van den Hurk","year":"2012","journal-title":"Biochim Biophy Acta"},{"key":"R2-33-20210309","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc3218","article-title":"From genes to drugs: targeted strategies for melanoma.","volume":"12","author":"Flaherty","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"R3-33-20210309","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer.","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"R4-33-20210309","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma.","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"key":"R5-33-20210309","first-page":"3728","article-title":"Mitogen-actived protein kinase activation is an early event in melanoma progression.","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin Cancer Res"},{"key":"R6-33-20210309","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nrd3579","article-title":"Vemurafenib.","volume":"10","author":"Flaherty","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"R7-33-20210309","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"R8-33-20210309","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.bcp.2013.11.013","article-title":"Emerging insights into resistance to BRAF inhibitors in melanoma.","volume":"87","author":"Bucheit","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"R9-33-20210309","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"R10-33-20210309","doi-asserted-by":"crossref","first-page":"464","DOI":"10.2353\/jmoldx.2007.060191","article-title":"Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma.","volume":"9","author":"Spittle","year":"2007","journal-title":"J Mol Diagn"},{"key":"R11-33-20210309","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2353\/jmoldx.2009.080100","article-title":"Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors.","volume":"11","author":"Pichler","year":"2009","journal-title":"J Mol Diagn"},{"key":"R12-33-20210309","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.mcp.2004.05.004","article-title":"Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E.","volume":"18","author":"Jarry","year":"2004","journal-title":"Mol Cell Probes"},{"key":"R13-33-20210309","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/bjc.2013.29","article-title":"BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma.","volume":"108","author":"Wilmott","year":"2013","journal-title":"Br J Cancer"},{"key":"R14-33-20210309","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/PAS.0b013e31826485c0","article-title":"Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.","volume":"37","author":"Long","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R16-33-20210309","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/annonc\/mds534","article-title":"Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients.","volume":"24","author":"Ilie","year":"2013","journal-title":"Ann Oncol"},{"key":"R17-33-20210309","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-011-0887-y","article-title":"Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases.","volume":"123","author":"Capper","year":"2012","journal-title":"Acta Neuropathol"},{"key":"R18-33-20210309","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00401-011-0841-z","article-title":"Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.","volume":"122","author":"Capper","year":"2011","journal-title":"Acta Neuropathol"},{"key":"R19-33-20210309","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5858\/arpa.2013-0031-OA","article-title":"Detection of BRAF p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility.","volume":"138","author":"Marin","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"R20-33-20210309","first-page":"49","article-title":"Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma Front O","volume":"2","author":"Fisher","year":"2013","journal-title":"ncol"},{"key":"R21-33-20210309","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature12627","article-title":"Tumour heterogeneity in the clinic.","volume":"501","author":"Bedard","year":"2013","journal-title":"Nature"},{"key":"R22-33-20210309","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","article-title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.","volume":"152","author":"Landau","year":"2013","journal-title":"Cell"},{"key":"R23-33-20210309","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma.","volume":"120","author":"Keats","year":"2012","journal-title":"Blood"},{"key":"R24-33-20210309","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/sj.bjc.6606072","article-title":"Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression.","volume":"104","author":"Lin","year":"2011","journal-title":"Br J Cancer"},{"key":"R25-33-20210309","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAFNRAS mutation frequencies among primary tumors and metastases in patients with melanoma.","volume":"30","author":"Colombino","year":"2012","journal-title":"J Clin Oncol"},{"key":"R26-33-20210309","doi-asserted-by":"crossref","first-page":"e29336","DOI":"10.1371\/journal.pone.0029336","article-title":"Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.","volume":"7","author":"Yancovitz","year":"2012","journal-title":"PLoS ONE"},{"key":"R27-33-20210309","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1158\/1535-7163.MCT-12-0530","article-title":"Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine.","volume":"11","author":"Wilmott","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"R28-33-20210309","doi-asserted-by":"crossref","first-page":"e70826","DOI":"10.1371\/journal.pone.0070826","article-title":"Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing.","volume":"8","author":"Boursault","year":"2013","journal-title":"PLoS ONE"},{"key":"R29-33-20210309","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/PAS.0000000000000136","article-title":"Intrapatient homogeneity of BRAFV600E expression in melanoma.","volume":"38","author":"Menzies","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R31-33-20210309","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/ncb2764","article-title":"A screen for morphological complexity identifies regulators of switch-like transitions between discrete cell shapes.","volume":"15","author":"Yin","year":"2013","journal-title":"Nat Cell Biol"},{"key":"R32-33-20210309","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/BF00372134","article-title":"Epithelioid cell melanomas have greater DNA ploidy abnormalities than spindle cell melanomas: cytological evidence for a higher malignant potential of the former.","volume":"285","author":"Chi","year":"1993","journal-title":"Arch Dermatol Res"},{"key":"R33-33-20210309","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1023\/A:1026555604250","article-title":"Epithelioid cell-type melanoma as a prognostic factor of poor response to immunological treatment.","volume":"11","author":"Ascierto","year":"2000","journal-title":"Ann Oncol"},{"key":"R34-33-20210309","first-page":"1005","article-title":"Frequent intra-tumoural heterogeneity of promoter hypermethylation in malignant melanoma.","volume":"22","author":"Rastetter","year":"2007","journal-title":"Histol Histopathol"},{"key":"R35-33-20210309","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1371\/journal.pmed.0050120","article-title":"Improving melanoma classification by integrating genetic and morphologic features.","volume":"5","author":"Viros","year":"2008","journal-title":"PLoS Med"},{"key":"R36-33-20210309","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ejca.2012.08.018","article-title":"(18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma.","volume":"49","author":"Carlino","year":"2013","journal-title":"Eur J Cancer"},{"key":"R37-33-20210309","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jmoldx.2012.10.002","article-title":"Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma.","volume":"15","author":"Greaves","year":"2013","journal-title":"J Mol Diagn"},{"key":"R38-33-20210309","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.","volume":"29","author":"Long","year":"2011","journal-title":"J Clin Oncol"},{"key":"R39-33-20210309","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.cmr.0000232300.22032.86","article-title":"NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.","volume":"16","author":"Edlundh-Rose","year":"2006","journal-title":"Melanoma Res"},{"key":"R40-33-20210309","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.1158\/0008-5472.CAN-04-0937","article-title":"Immunogenicity of constitutively active V599EBRaf.","volume":"64","author":"Andersen","year":"2004","journal-title":"Cancer Res"},{"key":"R41-33-20210309","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nature03890","article-title":"BRAFE600-associated senescence-like cell cycle arrest of human naevi.","volume":"436","author":"Michaloglou","year":"2005","journal-title":"Nature"},{"key":"R42-33-20210309","first-page":"3883","article-title":"BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.","volume":"63","author":"Dong","year":"2003","journal-title":"Cancer Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000000285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:39:04Z","timestamp":1620959944000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201412030-00033"}},"subtitle":["A STROBE-Compliant article"],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":40,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000000285","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}